CAS 1402152-13-9

Formel: C23H30Cl2N8O4

InChl: InChI=1S/C23H28N8O4.2ClH/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15;;/h3-4,13-14,25H,2,5-12H2,1H3,(H2,24,26,27);2*1H

InChI Key: KWVVOPDWPMORCQ-UHFFFAOYSA-N

SMILES: COC1=C(C=CC2=C3NCCN3C(=NC(=O)C4=CN=C(N=C4)N)N=C21)OCCCN5CCOCC5.Cl.Cl

Copanlisib dihydrochloride

CAS: 1402152-13-9

Copanlisib dihydrochloride: ATP-competitive PI3K inhibitor, potent for PI3Kα/δ/β/γ, antitumor, 2000x selectivity over other kinases except mTOR.

Formel: C₂₃H₃₀Cl₂N₈O₄

Reinheit: 99.05% - 99.16%

Farbe und Form: Solid

Molekulargewicht: 553.442

Ref: TM-T14998

Copanlisib dihydrochloride

CAS: 1402152-13-9

Copanlisib dihydrochloride

Formel: C₂₃H₃₀Cl₂N₈O₄

Reinheit: 99%

Molekulargewicht: 553.44

Ref: 54-BUP06251

Copanlisib dihydrochloride

CAS: 1402152-13-9

Formel: C₂₃H₃₀Cl₂N₈O₄

Reinheit: 99%

Farbe und Form: Solid

Molekulargewicht: 553.4415

Ref: IN-DA01V4KU

Copanlisib dihydrochloride

CAS: 1402152-13-9

Copanlisib is a small molecule that targets the PI3K-Akt pathway. It has been shown to be an effective treatment for cancer cells with the PD-L1 protein. Copanlisib is a pan-PI3K inhibitor, which means it inhibits all three isoforms of the enzyme: PI3Kα, PI3Kβ, and PI3Kγ. Copanlisib has shown clinical efficacy in patients with advanced solid tumours who are resistant to other treatments. This drug has also been shown to have hepatotoxic effects in mice, although this effect was not observed in humans.

Formel: C₂₃H₃₀Cl₂N₈O₄

Reinheit: Min. 95%

Molekulargewicht: 553.44 g/mol

Ref: 3D-CGC15213